Symptoms in Pediatric Cancer Do Not Coincide with Proxy Reports
the Cancer Therapy Advisor take:
Symptoms are common among children diagnosed with cancer; however, children’s reports of these symptoms do not coincide with proxy reports, according to an article published online in the journal Cancer.
In this study, 60 pediatric patients with cancer and their family caregivers completed the pediatric Memorial Symptom Assessment Scale (pMSAS), which was translated into Spanish.
The median age of the children was 10 years (range, 7 to 18 years) and 62% were male. Approximately 33% of the patients were Spanish-speaking, but the English- and Spanish-speaking participants yielded similar results.
Results showed nine patients (15%) reported no symptoms, while 38 (63%) had greater than or equal to 2 symptoms. Among the younger patients who reported symptoms, fatigue (12 patients; 40%) and itch (9 patients; 30%) were the most common; whereas, pain (15 patients; 50%) and lack of energy (13 patients; 45%) were the most common symptoms among the older children.
The authors noted 14 oncologists completed 25 patients’ pMSAS.
Furthermore, the range of agreement for individual symptoms between the patient and proxy was from a kappa of -0.30 (95% CI: -0.43, -0.01) to 0.91 (95% CI: 0.75, 1.00).
Out of 51 patients with demonstrated symptoms, 3 (6%) had documented treatment recommendations in their electronic health records.
Symptoms are common among children diagnosed with cancer; however, children’s reports of these symptoms do not match proxy reports.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Plastics and Cancer
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer